Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AS MDI · 1 trial · 1 indication
Forced expiratory volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation
| Arm | Type | Description |
|---|---|---|
| AS MDI | EXPERIMENTAL | AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Proventil | ACTIVE_COMPARATOR | Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Name | Type | Description |
|---|---|---|
| AS MDI | DRUG | AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Proventil | DRUG | Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation |
Inclusion Criteria: * Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis * Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to me...
AS MDI is an investigational small molecule being developed for the treatment of asthma. It is a pressurized inhalation suspension of albuterol sulfate, intended for use in patients with asthma. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AS MDI is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of asthma.
AS MDI is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of asthma, and its clinical development is ongoing.
AS MDI has one completed Phase 2 clinical trial, identified as NCT03371459. This trial assessed the safety, efficacy, pharmacokinetics, and extrapulmonary pharmacodynamics of AS MDI compared to Proventil as an active control in subjects with asthma. The trial enrolled 46 participants in the United States.
AS MDI contains albuterol sulfate, a bronchodilator that works by relaxing the muscles in the airways to improve breathing. It is administered as a pressurized inhalation suspension, delivering the medication directly to the lungs to relieve asthma symptoms.
AS MDI is a formulation of albuterol sulfate delivered as a pressurized inhalation suspension. It is being developed as an alternative to existing albuterol products, such as Proventil, which was used as an active control in its clinical trial. The drug is not yet approved.